Amer Zeidan, MBBS, reviews data from the phase 3 COMMANDS trial investigating the first-line treatment of anemia associated with lower-risk myelodysplastic syndromes.
EP. 1: Diagnosing Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Amer Zeidan, MBBS, discusses the signs and symptoms of lower-risk MDS and the tests typically used for diagnosis.
EP. 2: Risk Stratification in MDS
Dr Amer Zeidan explains the criteria he uses to assess risk in MDS, and why it is important to initiate treatment for lower-risk patients early.
EP. 3: Historical First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia
Amer Zeidan, MBBS, explains the treatment options for patients with lower-risk MDS prior to the approval of luspatercept.
EP. 4: Luspatercept for Patients With Lower-Risk MDS: Data from the COMMANDS Trial
Dr Amer Zeidan details the design, patient population, and key efficacy and safety data from the phase 3 COMMANDS trial investigating luspatercept for the frontline treatment of lower-risk MDS with anemia.
EP. 5: Clinical Implications of the COMMANDS Trial in the Treatment of Lower-Risk MDS
Amer Zeidan, MBBS, closes his discussion with a look at the potential implications of the COMMANDS trial data on the treatment of lower-risk MDS in clinical practice.
2 Clarke Drive Cranbury, NJ 08512